Loading…
← CockpitCompetitor Analysis › 300119.SZ Tianjin Ringpu Bio-technology Co., Ltd. Class AOpen in the cockpit ↗

Tianjin Ringpu Bio-technology Co., Ltd. Class A300119.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Tianjin veterinary vaccine maker focused on poultry and livestock biologics for Chinese farms.

≈ A poultry-vaccine Zoetis, China-onlyMomentum strong 73
Mkt cap
$1.11B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$9.39M
20-day average traded
Fwd P/E
18.1×
forward earnings
ROIC−WACC
+0.1 pp
WACC 6.5%
Hurdle
-6 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥16.04
1D-3.0%
1W-3.4%
1M-2.1%
3M-18.5%
6M-6.6%
YTD-14.5%
1Y-21.4%
ATR %3.2%
52w lowhigh25.4% off high

What Tianjin Ringpu Bio-technology does

Tianjin veterinary vaccine maker focused on poultry and livestock biologics for Chinese farms.

Paid per dose of vaccine, so sales rise and fall with herd sizes and with outbreak pressure that pushes farms to immunise more. Each new vaccine needs its own state veterinary approval, which makes a pipeline of newly cleared products as important as the existing ones.

In one line: A poultry-vaccine Zoetis, China-only.

Products and services

  • Poultry vaccines
  • Livestock vaccines
  • Veterinary diagnostics

Customers

  • Poultry and livestock farms

Where it sits in the supply chain

  • Animal health
  • Veterinary biologics
  • Poultry and livestock vaccines

What could go right

  • Livestock/poultry herd rebuilding cycles

What could go wrong

  • Disease-cycle demand swings
  • State price controls on vaccines

Moat: narrow (regulatory licence). Licensed veterinary biologics producer within a state-regulated animal-health market.

Headquarters: Tianjin, China · Employees: 2,803

Named competitors

Tianjin Ringpu Bio-technology at a glance

Size Tianjin Ringpu Bio-technology (300119.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.11B, the 1963rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.04 on 18 Nov 2026.

Performance Over six months the shares fell 6.6%, against -7.1% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue fell 8.7% over the last twelve months (peer median -1.2%); the operating margin is 10.6% (peer median 5.4%).

Valuation It trades at 18.1× forward earnings against a peer median of 20.2× (6th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -6 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.1 points above its cost of capital (6.5% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 94300119.SZ 93
Six months, rebased to 100: Tianjin Ringpu Bio-technology against the median of its 20 peers (local-currency closes).

Tianjin Ringpu Bio-technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.52BCN¥3.39BCN¥3.06BCN¥2.70BCN¥2.08B
Revenue growth—+11%+13%+30%—
Gross profitCN¥1.49BCN¥1.30BCN¥1.18BCN¥1.12BCN¥956M
EBITDAn/aCN¥600MCN¥573MCN¥517MCN¥463M
Net incomeCN¥337MCN¥401MCN¥301MCN¥454MCN¥347M
Free cash flowCN¥251MCN¥204MCN¥588MCN¥200MCN¥37.0M
Capital expenditureCN¥267MCN¥176MCN¥185MCN¥252MCN¥372M
Total debtCN¥1.82BCN¥1.58BCN¥1.60BCN¥1.10BCN¥986M

Quarterly statements and history in the cockpit →

Tianjin Ringpu Bio-technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%VETO237690VIYASH006280PYCMEDCLCMHC600812OMER00255045470009891952BLUEJET600789BSLN6855NKTR300119.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Tianjin Ringpu Bio-technology is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×200×400×VETO237690VIYASH006280CMHC0009891952BLUEJET300119.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tianjin Ringpu Bio-technology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%VETO237690VIYASH600812002550000989BLUEJET600789BSLN300119.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tianjin Ringpu Bio-technology is the large dot.

Tianjin Ringpu Bio-technology competitors and peer comparison

Head to head with its named competitors (300119.SZ vs 600201.SS vs 603566.SS vs ZTS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Tianjin Ringpu Bio-technology 300119.SZ$1.11B-7%-9%11%18.1×4.9%
Jinyu Bio-Technology 600201.SS$1.93B-21%+22%10%59.0×23.4%
Pulike Biological Engineering 603566.SS$449M-21%-9%5%23.2×4.5%
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%

How Tianjin Ringpu Bio-technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tianjin Ringpu Bio-technology against its 20 peers (data as of 18 Nov 2026)
Measure300119.SZPeer medianRank in peer set
1-month return-2.1%-1.6%10th lowest of 21
6-month return-6.6%-7.1%9th highest of 20
Distance from 52-week high-25.4%-32.1%9th highest of 21
Revenue growth (TTM)-8.7%-1.2%5th lowest of 17
Operating margin10.6%5.4%8th highest of 18
Forward P/E18.1×20.2×6th cheapest of 13
Growth the price implies (Req g, 7 yrs)4.9%2.5%3rd most demanding of 10
Growth delivered (Del g)+11.3%+6.5%5th highest of 10
Hurdle (Req g minus delivered)-6.4 pp+4.6 pp4th least demanding of 10
ROIC minus cost of capital+0.1 pp-2.8 pp7th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%27.8×4.2%+21.7%
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%32.2×36.3%+20.4%
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a

Questions

Who are Tianjin Ringpu Bio-technology's main competitors?
Named competitors: Jinyu Bio-technology (600201.SS), Pulike Biological Engineering (603566.SS), Zoetis (ZTS). The cockpit's measured peer set (industry) also includes Vetoquinol (VETO.PA), ST Pharm (237690.KS), Viyash Scientific (VIYASH.NS), Symbiotec Pharmalab (SYMBIOTEC.NS), GC Biopharma (006280.KS), PYC Therapeutics (PYC.AX).
Is Tianjin Ringpu Bio-technology expensive compared with its peers?
On forward p/e it trades at 18.1× against a peer median of 20.2×, 6th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -6 pp: the price already allows for a slowdown.
How has Tianjin Ringpu Bio-technology stock performed?
Over six months to 18 Nov 2026 the shares returned -6.6% against -7.1% for the median peer; over one year -21.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.